Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose

Li, Yuelin; Womer, Richard B.; Silber, Jeffrey H.

doi:10.1016/j.ejca.2003.08.009

Cited by 312 publications

(270 citation statements)

References 26 publications

Supporting

Mentioning

248

Contrasting

Unclassified

Order By: Relevance

“…16 According to these criteria 22 out of 74 patients were excluded from further analysis; 14 patients were younger than 5 years, two patients have already suffered from renal insufficiency before start of cisplatin therapy and six patients have received cranial irradiation. Two patients, who had developed no hearing impairment, were also excluded from the study, as they have received cumulative cisplatin dosages of 80 and 120 mg/m 2 , respectively.…”

Section: Patientsmentioning

confidence: 99%

Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin

et al. 2007

View full text Add to dashboard Cite

Ototoxicity and nephrotoxicity are dose-limiting side effects of cisplatin. Megalin, a member of the low-density lipoprotein receptor family, is highly expressed in renal proximal tubular cells and marginal cells of the stria vascularis of the inner ear -tissues, which accumulate high levels of platinum-DNA adducts. On the assumption that the mechanisms of cisplatin-induced nephro-and ototoxicity involve megalin we analyzed the incidence of the non-synonymous single nucleotide polymorphisms (SNP) rs2075252 and rs4668123 in 25 patients who developed a distinct hearing loss during cisplatin therapy and in 25 patients without hearing impairment after cisplatin therapy. We found no association between cisplatin-induced ototoxicity and any allele of rs4668123 but observed a higher frequency of the A-allele of rs2075252 in the group with hearing impairment than in the group with normal hearing after cisplatin therapy (0.32 versus 0.14) (w 2 ¼ 5.83, Po0.02; odds ratio: 3.45; 95% confidence interval: 1.11-11.2) indicating that SNPs at the megalin gene might impact the individual susceptibility against cisplatin-induced ototoxicity.

show abstract

Section: Patientsmentioning

confidence: 99%

Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin

et al. 2007

View full text Add to dashboard Cite

show abstract

“…14,15 Intensive induction therapy and ASCT have improved the outcomes of older children and those with MYCN amplified disease. 6,10 Late regimen-related toxicities have increasingly been recognized and include second malignancy, 17 hearing loss [18][19][20] and multiple endocrinopathies. [21][22][23][24] Despite this, neuropsychological and adaptive functioning appear to be well preserved.…”

Section: Introductionmentioning

confidence: 99%

Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation

Trahair

Vowels

Johnston

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

“…A major complication that limits the clinical use of cisplatin is the risk of drug-induced ototoxicity that can result in life-long disability 4 . Cisplatin ototoxicity manifests as permanent, bilateral hearing loss which affects 10-25% of adults and 26 -90% of children [5][6][7][8] . In particular, even mild hearing loss in children can significantly influence speech and language development, social-emotional development and increase the risk of learning difficulties 9 .…”

Section: Cisplatinmentioning

confidence: 99%

“…• Younger age at time of treatment, patients less than 5 years of age have 20 times higher risk compared to similarly treated older patients 71 . Age reported to have inverse relationship with hearing loss severity 72 .…”

Section: Box 1 Clinical Risk Factors For Cisplatin-induced Ototoxicitymentioning

confidence: 99%

Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers

Lee

Pussegoda

Rassekh

et al. 2016

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

Abstract:Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review summarizes findings from pharmacogenomic studies that report genetic polymorphisms associated with cisplatin-induced hearing loss and aims to (1) provide up-to-date information on new developments in the field; (2) provide recommendations for the use of pharmacogenetic testing in the prevention, assessment and management of cisplatin-induced hearing loss in children and adults; and (3) identify knowledge gaps to direct and prioritize future research. These practice recommendations for pharmacogenetic testing in the context of cisplatin-induced hearing loss reflect a review and evaluation of recent literature and are designed to assist clinicians in providing optimal clinical care for patients receiving cisplatin based chemotherapy.

show abstract

Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose

Cited by 312 publications

References 26 publications

Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin

Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin

Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation

Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers

Contact Info

Product

Resources

About